Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation

Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to enhanced apoptosis. Although...

Descripción completa

Detalles Bibliográficos
Autores principales: ABD-AZIZ, NORAINI, STANBRIDGE, ERIC J., SHAFEE, NORAZIZAH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579903/
https://www.ncbi.nlm.nih.gov/pubmed/26622817
http://dx.doi.org/10.3892/ol.2015.3545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579903/
https://www.ncbi.nlm.nih.gov/pubmed/26622817
http://dx.doi.org/10.3892/ol.2015.3545

Ejemplares similares